Harvard Bioscience Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
14
Price Target
$10.00
Consensus
Outperform
Upside
246.02%
Analysts
0
Stock Rating
14
Upside
246.02%
Analysts
0
Price Target
$10.00

Harvard Bioscience Stock Forecast and Price Target

Given the average yearlong price target of $10.00 provided by prominent analysts over the past few months, there is a potential upside of approximately 246.02% from the last closing price in January, 2023 for Harvard Bioscience's stock if it is reached. This estimation is based on a high estimate of $10.00 and a low estimate of $10.00. If you're interested in investing in this company, why not also look at its competitors to see how they are doing?

$10.00

246.02% Upside

Buy
Buy

Harvard Bioscience Fair Value Forecast for 2023 - 2025 - 2030

Harvard Bioscience's Price has seen impressive growth In the last two years, rising from $3.94 to $5.47 – a growth of 38.89%. In the next year, 0 analysts estimate that Harvard Bioscience's Fair Value will decrease by 19.83%, reaching $4.39. According to professional forecasts, in 2030, Harvard Bioscience's Fair Value will decrease by 17.50%, reaching $4.51.

2022 Fair Value Forecast
$4.39
2023 Fair Value Forecast
$4.40
2024 Fair Value Forecast
$4.23
2025 Fair Value Forecast
$4.63
2026 Fair Value Forecast
$4.56
2027 Fair Value Forecast
$4.51
2028 Fair Value Forecast
$4.42
2029 Fair Value Forecast
$4.49
2030 Fair Value Forecast
$4.51
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
TMO Stock Forecast Thermo Fisher Scientific Inc Outperform 10
$587.76 $618.99 5.49%
DHR Stock Forecast Danaher Corp Outperform 10
$269.85 $304.24 12.84%
BDX Stock Forecast Becton, Dickinson and Outperform 17
$245.84 $268.00 11.86%
LONN Stock Forecast Lonza Group Ltd Outperform 16
CHF457.90 CHF756.46 71.98%
PKI Stock Forecast PerkinElmer Outperform 16
$138.56 $159.83 17.28%

Harvard Bioscience Revenue Forecast for 2023 - 2025 - 2030

Harvard Bioscience's Revenue has seen impressive growth In the last two years, rising from $116.18M to $118.90M – a growth of 2.34%. In the next year, 0 analysts estimate that Harvard Bioscience's Revenue will decrease by 4.82%, reaching $113.17M. According to professional forecasts, in 2030, Harvard Bioscience's Revenue will decrease by 4.75%, reaching $113.26M.

2022 Rev Forecast
$0.11B
2023 Rev Forecast
$0.11B
2024 Rev Forecast
$0.11B
2025 Rev Forecast
$0.11B
2026 Rev Forecast
$0.11B
2027 Rev Forecast
$0.11B
2028 Rev Forecast
$0.11B
2029 Rev Forecast
$0.11B
2030 Rev Forecast
$0.11B

Harvard Bioscience Dividend per Share Forecast for 2023 - 2025 - 2030

Harvard Bioscience Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Harvard Bioscience's Free Cash Flow has decreased by 99.12%, going from $6.83M to $60.00k. Analysts predict that Harvard Bioscience's Free Cash Flow will increase in the upcoming year, reaching $5.47M. This would represent an increase of 9016.72%. Over the next nine years, experts predict that Harvard Bioscience's Free Cash Flow will grow at a rate of 705727503.16%.

2022 FCF Forecast
$0.01B
2023 FCF Forecast
$0.25B
2024 FCF Forecast
$11.37B
2025 FCF Forecast
$0.21B
2026 FCF Forecast
$3.79B
2027 FCF Forecast
$69.18B
2028 FCF Forecast
$1262.72B
2029 FCF Forecast
$69.24B
2030 FCF Forecast
$423.44B

Harvard Bioscience Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Harvard Bioscience's Net Income has decreased from $-4.69M to $-290.00k – a 93.82% drop. In the next year, analysts predict that Net Income will jump to $-5.26M – up 1715.42% from the current level. Looking ahead to nine years, experts forecast that Net Income will grow by 280473.41%.

2022 NI Forecast
$-5264708.33
2023 NI Forecast
$-48411800.97
2024 NI Forecast
$-437236021.64
2025 NI Forecast
$-40007095.98
2026 NI Forecast
$-148671702.94
2027 NI Forecast
$-560432851.40
2028 NI Forecast
$-2141488649.59
2029 NI Forecast
$-568279704.65
2030 NI Forecast
$-813662881.11

Harvard Bioscience EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Harvard Bioscience's EBITDA has decreased from $9.81M to $9.69M – a 1.22% drop. For the following year, the 0 analysts predict that Harvard Bioscience's EBITDA will drop by 4.34%, reaching $9.27M. In 2030, the professionals' prediction is that HBIO's EBITDA will decrease by 4.44%, reaching $9.26M.

2022 EBITDA Forecast
$0.01B
2023 EBITDA Forecast
$0.01B
2024 EBITDA Forecast
$0.01B
2025 EBITDA Forecast
$0.01B
2026 EBITDA Forecast
$0.01B
2027 EBITDA Forecast
$0.01B
2028 EBITDA Forecast
$0.01B
2029 EBITDA Forecast
$0.01B
2030 EBITDA Forecast
$0.01B

Harvard Bioscience EBIT Forecast for 2023 - 2025 - 2030

Harvard Bioscience's EBIT has decreased by 0.00% In the last two years, from $2.07M to $2.07M. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $6.64M – an increase of 220.72%. Over the next nine years, experts anticipate that EBIT growth for Harvard Bioscience will be 652.51%.

2022 EBIT Forecast
$0.01B
2023 EBIT Forecast
$0.02B
2024 EBIT Forecast
$0.01B
2025 EBIT Forecast
$0.01B
2026 EBIT Forecast
$0.01B
2027 EBIT Forecast
$0.03B
2028 EBIT Forecast
$0.01B
2029 EBIT Forecast
$0.01B
2030 EBIT Forecast
$0.02B

Harvard Bioscience EPS Price Prediction Forecast for 2023 - 2025 - 2030

Harvard Bioscience's EPS has seen impressive growth In the last two years, rising from $0.18 to $0.25 – a growth of 38.89%. In the next year, 0 analysts estimate that Harvard Bioscience's EPS will decrease by 19.83%, reaching $0.20. According to professional forecasts, in 2030, Harvard Bioscience's EPS will decrease by 17.50%, reaching $0.21.

2022 EPS Forecast
$0.20
2023 EPS Forecast
$0.20
2024 EPS Forecast
$0.19
2025 EPS Forecast
$0.21
2026 EPS Forecast
$0.21
2027 EPS Forecast
$0.21
2028 EPS Forecast
$0.20
2029 EPS Forecast
$0.21
2030 EPS Forecast
$0.21